8-K: Tourmaline Bio Stockholders Elect Directors, Ratify Auditor at 2025 Annual Meeting

Tourmaline Bio, Inc. announced the successful election of Dr. Caley Castelein and Aaron Kantoff as Class I directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 annual meeting of stockholders.

Summary

• Tourmaline Bio, Inc. held its 2025 annual meeting of stockholders on June 4, 2025.
• A total of 25,684,479 shares of common stock were entitled to vote as of the April 15, 2025 record date.
• There were 20,804,265 shares of common stock present virtually or represented by proxy, constituting a quorum to conduct business.
• Stockholders elected Dr. Caley Castelein and Aaron Kantoff as Class I directors to the Company's board of directors, each to serve until the 2028 annual meeting of stockholders.
• Dr. Caley Castelein received 14,926,508 votes For, 2,653,512 votes Withheld, and 3,224,245 Broker Non-Votes.
• Aaron Kantoff received 16,496,989 votes For, 1,083,031 votes Withheld, and 3,224,245 Broker Non-Votes.
• Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of Deloitte & Touche LLP received 20,799,312 votes For, 3,257 votes Against, and 1,696 Abstentions.

Sentiment

Score: 7

Explanation: The document reports the successful completion of routine corporate governance matters, including the election of directors and ratification of the auditor, with strong stockholder support. This indicates stable corporate operations and adherence to governance standards.

Positives

• Key corporate governance proposals, including the election of directors and ratification of the auditor, were successfully approved by stockholders with significant majority votes.
• A robust quorum was met with 20,804,265 shares present or represented by proxy, indicating strong stockholder engagement and participation.
• The election of Dr. Caley Castelein and Aaron Kantoff ensures continuity and stability on the Board of Directors until the 2028 annual meeting.

Industry Context

This 8-K filing details routine corporate governance matters, specifically the outcomes of an annual stockholder meeting. Such filings are standard practice for publicly traded companies and do not typically reflect broader industry trends, but rather the internal operational and governance health of the company.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Their votes directly influenced the composition of the Board of Directors and the appointment of the independent auditor, affirming their governance rights.
• **Board of Directors**: The election of Class I directors ensures the continued functioning and strategic oversight provided by the board.
• **Management**: The ratification of the auditor provides external validation and oversight of financial reporting, supporting management's accountability.

Next Steps

• The elected Class I directors, Dr. Caley Castelein and Aaron Kantoff, will serve until the 2028 annual meeting of stockholders.
• Deloitte & Touche LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Tourmaline Bio, TRML, SEC Filing, 8-K, Annual Meeting, Stockholders Meeting, Corporate Governance, Director Election, Auditor Ratification, Board of Directors, Deloitte & Touche